These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37530622)

  • 1. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
    Ansell SM; Bröckelmann PJ; von Keudell G; Lee HJ; Santoro A; Zinzani PL; Collins GP; Cohen JB; de Boer JP; Kuruvilla J; Savage KJ; Trněný M; Provencio M; Jäger U; Willenbacher W; Wen R; Akyol A; Mikita-Geoffroy J; Shipp MA; Engert A; Armand P
    Blood Adv; 2023 Oct; 7(20):6266-6274. PubMed ID: 37530622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
    J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
    Harker-Murray P; Mauz-Körholz C; Leblanc T; Mascarin M; Michel G; Cooper S; Beishuizen A; Leger KJ; Amoroso L; Buffardi S; Rigaud C; Hoppe BS; Lisano J; Francis S; Sacchi M; Cole PD; Drachtman RA; Kelly KM; Daw S
    Blood; 2023 Apr; 141(17):2075-2084. PubMed ID: 36564047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
    Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Lisano J; Wen R; Akyol A; Moskowitz AJ
    Blood Adv; 2023 Sep; 7(18):5272-5280. PubMed ID: 37352266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
    Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
    Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Manley T; Francis S; Sharma M; Moskowitz AJ
    J Clin Oncol; 2019 Nov; 37(33):3081-3089. PubMed ID: 31398081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
    Chen R; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Huebner D; Fong A; Younes A
    Blood; 2016 Sep; 128(12):1562-6. PubMed ID: 27432875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
    Friedberg JW; Bordoni R; Patel-Donnelly D; Larson T; Goldschmidt J; Boccia R; Cline VJM; Mamidipalli A; Liu J; Akyol A; Yasenchak CA
    Blood; 2024 Feb; 143(9):786-795. PubMed ID: 37946283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
    Maruyama D; Hatake K; Kinoshita T; Fukuhara N; Choi I; Taniwaki M; Ando K; Terui Y; Higuchi Y; Onishi Y; Abe Y; Kobayashi T; Shirasugi Y; Tobinai K
    Cancer Sci; 2017 May; 108(5):1007-1012. PubMed ID: 28267244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
    Moretti M; Liberati AM; Rigacci L; Puccini B; Pulsoni A; Gini G; Galieni P; Fabbri A; Cantonetti M; Pavone V; Bolis S; Botto B; Renzi D; Falchi L
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):198-204. PubMed ID: 34690088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
    Mei MG; Lee HJ; Palmer JM; Chen R; Tsai NC; Chen L; McBride K; Smith DL; Melgar I; Song JY; Bonjoc KJ; Armenian S; Nwangwu M; Lee PP; Zain J; Nikolaenko L; Popplewell L; Nademanee A; Chaudhry A; Rosen S; Kwak L; Forman SJ; Herrera AF
    Blood; 2022 Jun; 139(25):3605-3616. PubMed ID: 35316328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
    Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
    Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
    Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
    Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
    Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A
    J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
    Armand P; Zinzani PL; Lee HJ; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Herrera AF; Lin J; Kim E; Chakraborty S; Marinello P; Moskowitz CH
    Blood; 2023 Sep; 142(10):878-886. PubMed ID: 37319435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
    Advani RH; Moskowitz AJ; Bartlett NL; Vose JM; Ramchandren R; Feldman TA; LaCasce AS; Christian BA; Ansell SM; Moskowitz CH; Brown L; Zhang C; Taft D; Ansari S; Sacchi M; Ho L; Herrera AF
    Blood; 2021 Aug; 138(6):427-438. PubMed ID: 33827139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.